Last update Aug. 1, 2022
Likely Compatibility
We do not have alternatives for Naloxone Hydrochloride.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Naloxone Hydrochloride is also known as
Naloxone Hydrochloride in other languages or writings:
Naloxone Hydrochloride belongs to these groups or families:
Main tradenames from several countries containing Naloxone Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | ≈ 0 | % |
Molecular weight | 400 | daltons |
Protein Binding | 45 | % |
VD | 2.86 | l/Kg |
pKa | 10.07 | - |
Tmax | 0.05 - 0.25 | hours |
T½ | 1 - 1.5; intranasal: 1.8 - 2.7 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an opioid antagonist used to reverse respiratory and neurological depression induced by opioid overdose. It acts by blocking the opioid receptors, not on the concentration or elimination of the opioid drug involved. Intravenous, intramuscular, subcutaneous or intranasal administration.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data do not allow to predict a possible excretion in breast milk.
Given the low plasma levels of Naloxone after a treatment dose (<0,1micrograms/mL), the maximum concentration that it would reach in breast milk would imply a theoretical dose for the infant that is much lower than that used in Pediatrics.
Its null oral bioavailability prevents the passage to the infant's plasma from ingested breast milk.
Experts authors consider the use of this medication to be probably compatible during breastfeeding (Hale, LactMed, Briggs 2015, ASGE 2012, Mahadevan 2006); temporary interruption of breastfeeding will depend on opiate elimination and maternal symptoms, not on naloxone. (Hale, LactMed, Briggs 2015)